MRNA Moderna, Inc.
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as intismeran autogene, cancer antigen therapy, t-cell engager, and cell therapy enhancer; and rare disease products, including propionic and methylmalonic acidemia, and cystic fibrosis. It has strategic alliances and collaborations with Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; immatics N.V.; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.…
Industry Peers
BiotechnologyKey Statistics
About Moderna (NASDAQ: MRNA)
›
Moderna (NASDAQ: MRNA) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 4,700 employees.
The shares were at 194.04 USD on 20 November 2026, up 719.3% over 52 weeks. Its 52-week range is 22.28 USD to 280.80 USD: the price is 30.9% below the high and 770.9% above the low.
Its market capitalisation is 80.65B USD.
Moderna reports return on equity of -32.6%, an operating margin of -80.8% and revenue up 29.2% year over year.
It holds more cash than debt, a net cash position of 942.00M USD. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. 19 analysts cover the stock, with an average rating of Hold; their mean price target of 164.53 USD is 15.2% below the current price. The next earnings report is expected on 12 February 2027.